A Product I Never Expected to Discuss Again — 2026-07-27
Core thesis: The CME's reintroduction of single stock futures (SSFs) is a direct response to explosive retail demand for leveraged exposure to individual stocks, as evidenced by surging popularity of leveraged ETFs. SSFs address a real structural gap: they offer lower margin requirements (as low as 15%) and avoid the decay drag that plagues options-embedded leveraged ETFs.
Key points:
- SSFs failed historically in the US because margin advantages were irrelevant during low-rate environments post-GFC; today's higher rates and retail appetite for leverage have changed the calculus.
- Unlike leveraged ETFs (which decay due to embedded options), futures expire but don't decay—a material performance advantage for speculative traders.
- The new CME product targets retail with 10x multipliers (not 100x), making leveraged single-stock bets more accessible to smaller accounts.
- Previous SSF attempts (OneChicago, NQLX) never gained traction; success now depends entirely on whether retail perceives adequate liquidity and appeal.
- This is explicitly a speculative product aimed at individual investors, not institutions—raising questions about market stability if adoption accelerates.
Takeaway: Watch adoption metrics and liquidity depth closely. If SSFs gain traction, they could cannibalize leveraged ETF flows and shift retail leverage from daily-rebalancing drag into futures markets—a structural shift with implications for single-stock volatility and margin dynamics.